Free Trial
NASDAQ:REPL

Replimune Group Q2 2024 Earnings Report

Replimune Group logo
$9.94 -0.07 (-0.66%)
As of 10:08 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Replimune Group EPS Results

Actual EPS
-$0.90
Consensus EPS
-$0.80
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

Replimune Group Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Replimune Group Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Tuesday, November 7, 2023
Conference Call Time
8:00AM ET

Upcoming Earnings

Replimune Group's Q4 2025 earnings is scheduled for Thursday, May 15, 2025, with a conference call scheduled on Friday, May 16, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Replimune Group Earnings Headlines

Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
Replimune Group Inc.
Replimune price target raised to $18 from $16 at JPMorgan
See More Replimune Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Replimune Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Replimune Group and other key companies, straight to your email.

About Replimune Group

Replimune Group (NASDAQ:REPL), a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

View Replimune Group Profile

More Earnings Resources from MarketBeat